Key result
Ivabradine in POTS is linked to a ~25 bpm lower standing heart rate increase and improved symptoms.
Why the study?
It remains unclear whether tachycardia in POTS is compensatory for a reduced stroke volume or is itself causing symptoms.
Does ivabradine reduce heart rate and improve symptoms in patients with Postural Orthostatic Tachycardia Syndrome?
Observational
Does ivabradine reduce heart rate and improve symptoms in patients with Postural Orthostatic Tachycardia Syndrome?
p-value: p=0.011
Ivabradine significantly reduces standing heart rate and symptom burden in patients with POTS, suggesting tachycardia is central to POTS pathophysiology rather than compensatory.
May support symptom relief with ivabradine in POTS; hypothesis-generating pending randomized confirmation.
Postural orthostatic tachycardia syndrome (POTS) is a clinical syndrome of tachycardia on standing leading to palpitations, dizziness, chest pain, and/or fatigue. An exaggerated norepinephrine response with standing is often present in POTS, but it remains unclear whether the tachycardia is compensatory for a reduced stroke volume or whether the tachycardia is itself causing the symptoms of POTS. We herein report the effects of heart rate (HR) lowering with ivabradine, a selective I f channel blocker, on symptom burden in patients with POTS. After ivabradine treatment, there was a significant reduction in the change in HR with standing in all patients from 40 (30-70) to 15 (8-19) bpm ( P = 0.011), without significant changes in blood pressure. The Malmö score was significantly reduced in all patients from 86 (74-92) to 39 (32-66) ( P = 0.005). A correlation between change in HR with standing and the change in Malmö score (R = +0.828; R 2 quadratic = 0.635; P < 0.001) was present. The parallel improvement in HR response and symptoms with ivabradine suggests that the tachycardia response in POTS may not be considered compensatory but rather central to the pathophysiology of POTS symptoms.
No takes yet. Share an insight, caveat, or question.
Marchetta et al. (2025) conducted an observational in Postural orthostatic tachycardia syndrome (POTS). Ivabradine was evaluated on Change in heart rate with standing and symptom burden (Malmö score) (p=0.011). Ivabradine treatment in patients with POTS significantly reduced the change in heart rate with standing from 40 to 15 bpm (P=0.011) and improved the Malmö score from 86 to 39 (P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: